Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transforming Growth Factor Beta

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Transforming Growth Factor Beta. Displaying page 1 of 1.
    EudraCT Number: 2005-005482-10 Sponsor Protocol Number: RN1001-0042 Start Date*: 2006-03-13
    Sponsor Name:Renovo
    Full Title: A double blind, placebo controlled, randomised dose response trial to investigate the efficacy of Juvista in the improvement of scar appearance when applied to approximated wound margins following ...
    Medical condition: Patients undergoing varicose vein removal with ligation and stripping.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) LV (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004938-24 Sponsor Protocol Number: RN1001-0098 Start Date*: 2009-03-24
    Sponsor Name:Renovo
    Full Title: A within patient, placebo controlled, proof of concept trial to assess the efficacy of Juvista in improving the appearance of existing scars that are 2-6 months old.
    Medical condition: Improvement of existing scars
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039589 Scarring LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004265-42 Sponsor Protocol Number: RN1001-0041 Start Date*: 2006-04-06
    Sponsor Name:Renovo
    Full Title: A double blind, placebo controlled, randomised trial to investigate the efficacy of Juvista in the improvement of scar appearance in patients undergoing bilateral reduction mammaplasty.
    Medical condition: Severe scarring following breast reduction surgery.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000994-30 Sponsor Protocol Number: VD1.3 Start Date*: 2013-02-19
    Sponsor Name:Medizinische Universität Graz
    Full Title: A randomized, double‐blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on metabolic and fertility parameters in PCOS women
    Medical condition: Polycystic Ovary Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002124-28 Sponsor Protocol Number: RN1001-0091 Start Date*: 2008-11-17
    Sponsor Name:Renovo Ltd
    Full Title: A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars.
    Medical condition: Improvement of scar appearance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039589 Scarring LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) HU (Completed) ES (Completed) DK (Completed) IT (Completed) DE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003575-11 Sponsor Protocol Number: VitaminD&TT Start Date*: 2013-03-05
    Sponsor Name:Medizinische Universität Graz, Innere Medizin
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men
    Medical condition: Male hypogonadism (total testosterone <3ng/ml)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10000193 Male sex hormone abnormalities HLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003818-24 Sponsor Protocol Number: DC2015RED01 Start Date*: 2015-12-11
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked trans...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001280-13 Sponsor Protocol Number: A536-05 Start Date*: 2014-09-03
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolle...
    Medical condition: Myelodysplastic Syndromes (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001547-12 Sponsor Protocol Number: DC2017RACELINES01 Start Date*: 2017-12-21
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003301-26 Sponsor Protocol Number: IAFIPF001 Start Date*: 2013-09-20
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002093-20 Sponsor Protocol Number: H9H-MC-JBEF Start Date*: 2017-03-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered i...
    Medical condition: Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non–Small Cell Lung Cancer or Hepatocellular Carcinoma, (Phase 2)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001626-26 Sponsor Protocol Number: OMT28-C0201 Start Date*: 2019-01-23
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (...
    Medical condition: Persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-002530-50 Sponsor Protocol Number: EspeRare_RIM_001 Start Date*: 2015-11-04
    Sponsor Name:EspeRare
    Full Title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005096-27 Sponsor Protocol Number: MBPS205 Start Date*: 2017-06-23
    Sponsor Name:Mereo BioPharma 3 Ltd.
    Full Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusu...
    Medical condition: Osteogenesis imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005036-26 Sponsor Protocol Number: FXT-05 Start Date*: 2011-11-29
    Sponsor Name:Funxional Therapeutics Ltd
    Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease
    Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001641-24 Sponsor Protocol Number: PYR-311 Start Date*: 2014-09-29
    Sponsor Name:NephroGenex
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin® (pyridoxamine dihydrochloride) in Subjects With Nephropathy Due to Type ...
    Medical condition: Nephropathy Due to Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004941-34 Sponsor Protocol Number: GFT505B-319-1 Start Date*: 2020-10-09
    Sponsor Name:GENFIT
    Full Title: A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Ina...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10034176 PBC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Completed) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005983-12 Sponsor Protocol Number: INT01/12 Start Date*: 2012-03-21
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of the fully human monoclonal antibody against transforming growth factor-beta (TGF-beta) receptor ALK1 (PF-03446962) in relapsed or refractory urothelial cancer (UC) failing first-l...
    Medical condition: Relapsed or refractory urothelial cancer after failure of 1st line platinum-containing chemotherapy regimen for metastatic disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038502 Renal pelvis and ureter neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044410 Transitional cell cancer of the renal pelvis and ureter recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044412 Transitional cell carcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066750 Bladder transitional cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021994-35 Sponsor Protocol Number: A4001098 Start Date*: 2011-06-30
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022338-10 Sponsor Protocol Number: H9H-MC-JBAK Start Date*: 2011-05-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma
    Medical condition: Carcinoma, hepatocellular
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 12:27:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA